Intern at Spike Pharma
Release time:
2020-07-15
In May last year, two female interns came to the packaging room of the preparation workshop of Jianfeng Pharmaceutical Factory. They smiled and helped the workers. But one day I found that they were a little different from the usual, not very energetic. I took the time to talk with them for a while. It turned out that their probation was about to end. I felt a little lost and reluctant to part with them.
One of the girls, Xiao Wu, was more talkative. She said that they were students majoring in pharmaceutical technology in the Golden Vocational College. They went to Jianfeng Pharmaceutical Factory for a month and received safety training at the headquarters, which enabled them to further understand the development and entrepreneurial history of Jianfeng. At the end of the training, Xiao Wu and several other students were arranged to study in Jinxi factory. "Jinxi's factory is very large and its management is very standardized. There are three dressing rooms alone, one for women's first, one for buffer and one for women's second. There are also many hand washing procedures, disinfection procedures and SOP written in great detail. The factory has very strict requirements on product quality. The position I was assigned was to pick up some drugs that were not packaged in place in front of the machine packaging machine. Products with quality problems cannot leave the factory." Xiao Wu has fresh memories of his work.
After studying in the Jinxi plant for half a month, Xiao Wu and another girl were transferred to the Akihama plant preparation workshop, "As soon as I arrived at the workshop, I saw an aunt mopping the floor, the whole workshop was dragged spotlessly, my house was not so clean. The staff in the clean area are all wearing clean clothes, masks and gloves, and the cleanliness requirements are very strict." Xiao Wu said this was her first impression of the preparation workshop. She learned a lot of things here that she couldn't learn in class, and felt a special sense of accomplishment. More than a month's internship also made Xiao Wu know more about the peak. She said that she hoped to be able to work at the peak after graduation, but she would continue to study for a junior college and then apply for a job at the peak after graduation. She would do her best to work at the peak and contribute to the development of the peak.
After chatting with Xiao Wu, I marveled at her confidence and persistence. If every trainee can love and support spikes like Xiao Wu, then our spike career will surely flourish, by going up one storey. (Hong Zhiwei)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page